188 related articles for article (PubMed ID: 25475034)
1. [The role of RNA splicing in the pathogenesis of spinal muscular atrophy and development of its therapeutics].
Sahashi K; Sobue G
Brain Nerve; 2014 Dec; 66(12):1471-80. PubMed ID: 25475034
[TBL] [Abstract][Full Text] [Related]
2. Therapeutics development for spinal muscular atrophy.
Sumner CJ
NeuroRx; 2006 Apr; 3(2):235-45. PubMed ID: 16554261
[TBL] [Abstract][Full Text] [Related]
3. SMN deficiency alters Nrxn2 expression and splicing in zebrafish and mouse models of spinal muscular atrophy.
See K; Yadav P; Giegerich M; Cheong PS; Graf M; Vyas H; Lee SG; Mathavan S; Fischer U; Sendtner M; Winkler C
Hum Mol Genet; 2014 Apr; 23(7):1754-70. PubMed ID: 24218366
[TBL] [Abstract][Full Text] [Related]
4. Spinal muscular atrophy phenotype is ameliorated in human motor neurons by SMN increase via different novel RNA therapeutic approaches.
Nizzardo M; Simone C; Dametti S; Salani S; Ulzi G; Pagliarani S; Rizzo F; Frattini E; Pagani F; Bresolin N; Comi G; Corti S
Sci Rep; 2015 Jun; 5():11746. PubMed ID: 26123042
[TBL] [Abstract][Full Text] [Related]
5. TSUNAMI: an antisense method to phenocopy splicing-associated diseases in animals.
Sahashi K; Hua Y; Ling KK; Hung G; Rigo F; Horev G; Katsuno M; Sobue G; Ko CP; Bennett CF; Krainer AR
Genes Dev; 2012 Aug; 26(16):1874-84. PubMed ID: 22895255
[TBL] [Abstract][Full Text] [Related]
6. The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy.
d'Ydewalle C; Ramos DM; Pyles NJ; Ng SY; Gorz M; Pilato CM; Ling K; Kong L; Ward AJ; Rubin LL; Rigo F; Bennett CF; Sumner CJ
Neuron; 2017 Jan; 93(1):66-79. PubMed ID: 28017471
[TBL] [Abstract][Full Text] [Related]
7. Development and characterization of an SMN2-based intermediate mouse model of Spinal Muscular Atrophy.
Cobb MS; Rose FF; Rindt H; Glascock JJ; Shababi M; Miller MR; Osman EY; Yen PF; Garcia ML; Martin BR; Wetz MJ; Mazzasette C; Feng Z; Ko CP; Lorson CL
Hum Mol Genet; 2013 May; 22(9):1843-55. PubMed ID: 23390132
[TBL] [Abstract][Full Text] [Related]
8. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy.
Brichta L; Hofmann Y; Hahnen E; Siebzehnrubl FA; Raschke H; Blumcke I; Eyupoglu IY; Wirth B
Hum Mol Genet; 2003 Oct; 12(19):2481-9. PubMed ID: 12915451
[TBL] [Abstract][Full Text] [Related]
9. Spinal muscular atrophy: the RNP connection.
Eggert C; Chari A; Laggerbauer B; Fischer U
Trends Mol Med; 2006 Mar; 12(3):113-21. PubMed ID: 16473550
[TBL] [Abstract][Full Text] [Related]
10. Stimulating full-length SMN2 expression by delivering bifunctional RNAs via a viral vector.
Baughan T; Shababi M; Coady TH; Dickson AM; Tullis GE; Lorson CL
Mol Ther; 2006 Jul; 14(1):54-62. PubMed ID: 16580882
[TBL] [Abstract][Full Text] [Related]
11. Nusinersen ameliorates motor function and prevents motoneuron Cajal body disassembly and abnormal poly(A) RNA distribution in a SMA mouse model.
Berciano MT; Puente-Bedia A; Medina-Samamé A; Rodríguez-Rey JC; Calderó J; Lafarga M; Tapia O
Sci Rep; 2020 Jul; 10(1):10738. PubMed ID: 32612161
[TBL] [Abstract][Full Text] [Related]
12. Is RNA manipulation a viable therapy for spinal muscular atrophy?
Horne C; Young PJ
J Neurol Sci; 2009 Dec; 287(1-2):27-31. PubMed ID: 19758605
[TBL] [Abstract][Full Text] [Related]
13. Spinal muscular atrophy.
Vitte J; Attali R; Warwar N; Gurt I; Melki J
Adv Exp Med Biol; 2009; 652():237-46. PubMed ID: 20225030
[TBL] [Abstract][Full Text] [Related]
14. A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy.
Kashima T; Manley JL
Nat Genet; 2003 Aug; 34(4):460-3. PubMed ID: 12833158
[TBL] [Abstract][Full Text] [Related]
15. Pathological impact of SMN2 mis-splicing in adult SMA mice.
Sahashi K; Ling KK; Hua Y; Wilkinson JE; Nomakuchi T; Rigo F; Hung G; Xu D; Jiang YP; Lin RZ; Ko CP; Bennett CF; Krainer AR
EMBO Mol Med; 2013 Oct; 5(10):1586-601. PubMed ID: 24014320
[TBL] [Abstract][Full Text] [Related]
16. Spinal muscular atrophy: recent advances and future prospects.
Nicole S; Diaz CC; Frugier T; Melki J
Muscle Nerve; 2002 Jul; 26(1):4-13. PubMed ID: 12115944
[TBL] [Abstract][Full Text] [Related]
17. Neurodevelopmental consequences of Smn depletion in a mouse model of spinal muscular atrophy.
Liu H; Shafey D; Moores JN; Kothary R
J Neurosci Res; 2010 Jan; 88(1):111-22. PubMed ID: 19642194
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells.
Grzeschik SM; Ganta M; Prior TW; Heavlin WD; Wang CH
Ann Neurol; 2005 Aug; 58(2):194-202. PubMed ID: 16049920
[TBL] [Abstract][Full Text] [Related]
19. Two breakthrough gene-targeted treatments for spinal muscular atrophy: challenges remain.
Sumner CJ; Crawford TO
J Clin Invest; 2018 Aug; 128(8):3219-3227. PubMed ID: 29985170
[TBL] [Abstract][Full Text] [Related]
20. Molecular and functional analysis of intragenic SMN1 mutations in patients with spinal muscular atrophy.
Sun Y; Grimmler M; Schwarzer V; Schoenen F; Fischer U; Wirth B
Hum Mutat; 2005 Jan; 25(1):64-71. PubMed ID: 15580564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
